Basel Medical Group Ltd(BMGL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.85 | Insider Own | 54.32% | Shs Outstand | 7.6M | Perf Week | 3.84% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 3.5M | Perf Month | 48.39% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | - | Inst Own | 0.01% | Short Float | 0.37% | Perf Quarter | -22.69% |
| Income | -0.01B | P/S | 3.13 | EPS this Y | - | Inst Trans | -9.54% | Short Ratio | 0.02 | Perf Half Y | -31.55% |
| Sales | 0.01B | P/B | 1.47 | EPS next 5Y | - | ROA | -57.05% | Short Interest | 0.01M | Perf YTD | -21.77% |
| Book/sh | 3.12 | P/C | 33.54 | EPS past 3/5Y | - | ROE | -148.66% | 52W High | -76.34% ($19.44) | Perf Year | -75.89% |
| Cash/sh | 0.14 | P/FCF | - | Sales past 3/5Y | 2.92% - | ROIC | -79.19% | 52W Low | 79.69% ($2.56) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1992.89% | Gross Margin | -2.33% | Volatility(W/M) | 3.87% 9.79% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 3.74 | Sales Y/Y TTM | 49.15% | Oper. Margin | -31.64% | ATR (14) | 0.39 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.84 | EPS Q/Q | 187.19% | Profit Margin | -68% | RSI (14) | 59.42 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.88 | Sales Q/Q | 68.79% | SMA20 | 17.9% ($3.9) | Beta | 0.43 | Target Price | - |
| Payout | - | Debt/Eq | 1.57 | Earnings | - | SMA50 | 4.45% ($4.4) | Rel Volume | 2.45 | Prev Close | $4.63 |
| Employees | - | LT Debt/Eq | 0.96 | EPS/Sales Surpr. | - | SMA200 | -30.29% ($6.6) | Avg Volume(3M) | 0.82M | Price | $4.6 |
| IPO | 2025/2/26 | Option/Short | No/Yes | Trades | 2170 | Volume | 2,013,587 | Change | -0.65% |
Basel Medical Group () is a healthcare company based in Singapore that provides a broad range of medical services, with a core focus on orthopedics, sports medicine, and neurosurgery, while also offering general practice, health screenings, rehabilitation, and occupational health services. After listing on Nasdaq in February 2025, the company acquired Bethesda Medical, expanding its general practice clinic network by six locations, and has since signed a major Asia-Pacific supply agreement with PanCare as it moves forward with plans to scale up operations, making it a newly listed small-cap medical name.
Over the past 1 year, on the lower side
76% below its 1-year high.
Traded more than usual. That is 245% of its average volume.
BMGL has a sound balance sheet but weak earning power
Of every $100 in sales, $31.64 is lost.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $313. Peers typically go for $94.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
EBIZ Global X E-commerce ETF <0.01% 
ISCF iShares International Small-Cap Equity Factor ETF <0.01% 
GWX State Street SPDR S&P International Small Cap ETF <0.01% 
AVDS Avantis International Small Cap Equity ETF <0.01% 
SPDW State Street SPDR Portfolio Developed World ex-US ETF <0.01% It ranks #43 of 48 in the industry
Based on market cap of $35M.
CCEL#41 Cryo-Cell International Inc $41M PER - 
BTMD#42 biote Corp $41M PER 9.6 BMGL#43 Basel Medical Group Ltd $35M PER - 
PIII#44 P3 Health Partners Inc $30M PER - 
DCGO#45 DocGo Inc $28M PER - 
FAQ
What kind of company is BMGL?
BMGL belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of BMGL?
The market cap of BMGL is approximately $35M, ranking 5,022 within its sector.
What is the 52-week high and low for BMGL?
BMGL has recorded a 52-week high of $19.44 and a low of $2.56.
